Immune responses to polysaccharides such as those found in bacterial capsules or some bacterial vaccines involve T cell independent antibody responses by B cells activated by Ig receptor cross-linking. Mice of the xid mutant strain are unresponsive to polysaccharide antigens and can serve as a model where activation of B cells by T independent (TI-2) antigens is deficient. They can be used to delineate factors required for immune responses to polysaccharides. These mice are reported to have a mutation in a B cell associated tyrosine kinase gene, btk, causing an arrest in TI-2 but not T dependent (TD) or TI-1 activation. Other effects of xid include low serum IgG3 levels, a missing subset of B cells, the Lyb-5+ B cells, and lower numbers of B cells. To investigate the effect of the xid mutation in B cell activation, events in xid and non-xid B cells activated in vitro by Ig crosslinking are being compared. TI-2 activation sets off a series of events in B cells, which proceed in a temporal order over a time course of up to 5 days. These events range from signaling events related to progression from G0 to G1 phase to DNA synthesis and other events associated with progression into S/G2 and M phase. Earlier studies performed in other labs have revealed that the immediate signaling events such as PI turn over and tyrosine phosphorylation are intact in xid B cells. Our extensive analysis has shown that other signaling events in xid B cells such as proto-oncogene and nuclear factor induction are intact, with late events more related to entry to cell cycle such as housekeeping gene up-regulation are diminished relative to non-xid. In addition, we find that sustained viability in culture of xid B cells is diminished relative to non-xid and is not effected by TI-2 activation. Further studies examining S/G2 entry in xid B cells will be pursued including examination of cyclin and cyclin dependent kinase activity in xid B cells. A clear understanding of the events associated with TI-2 activation is required to optimize immune responses to polysaccharide vaccines. This is especially important for vaccination of very young and elderly populations which respond poorly to polysaccharides.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Intramural Research (Z01)
Project #
1Z01BO003007-01
Application #
3748255
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost